Abstract
P2.14-06 A Phase II Trial Assessing the Safety and Efficacy of Tislelizumab Combined with Chemotherapy and Autologous NK Cells in Patients with ES-SCLC
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
